Frontlight ResearchEarly access
Metastatic breast cancer trials in Germany
52 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleLong-term follow-up of patients treated with GD2IL18CART
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 20
- Run by
- Universitaet Muenster
See details and how to join2025-521497-34-00 - Phase 3Taking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Berlin, Dresden, Duesseldorf, Erlangen, Frankfurt am Main, Frankfurt Am Main, Heidelberg, Muenster, Munich, Torgau, Ulm, Witten, Worms, Wuppertal
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - Phase 1Taking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Essen
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - No phaseTaking peoplePROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- Where
- Amberg, Ansbach, Apolda, Aschaffenburg, Augsburg, Baden-Baden, Bad Reichenhall, Balingen, Bamberg, Berlin, Bielefeld, Bonn, Brandenburg an der Havel, Braunschweig, Bremen, Bremerhaven, Coburg, Dessau, Donauwörth, Dortmund, Dresden, Düsseldorf, Eggenfelden, Erfurt, Essen, Filderstadt - Bonlanden, Frankfurt, Freudenstadt, Fürstenfeldbruck, Fürstenwalde, Gerlingen, Giessen, Halle, Hamburg, Hanover, Hansestadt Salzwedel, Heidenheim, Heilbronn, Hildesheim, Homburg/Saar, Jena, Kaiserslautern, Karlsruhe, Kassel, Kempten, Kiel, Krefeld, Kulmbach, Landshut, Leer, Leipzig, Loerrach, Lübeck, Lüneburg, Magdeburg, Mainz, Marburg, Memmingen, Mönchengladbach, Mühlhausen, München, Mutlangen, Neumarkt, Neuruppin, Neustadt am Rübenberge, Nordhausen, Nuremberg, Oldenburg, Oranienburg, Potsdam, Recklinghausen, Regensburg, Rosenheim, Rotenburg (Wümme), Saalfeld, Saarbrücken, Schwäbisch Hall, Siegen, Singen, Solingen, Stade, Stuttgart, Torgau, Troisdorf, Ulm, Walsrode, Weiden, Weinheim, Wessenfels, Westerstede, Wiesbaden, Winnenden, Witten, Wolfsburg, Wuppertal, Würzburg, Zittau
- Age
- 18 years to 130 years
- People
- 800
- Run by
- AstraZeneca
See details and how to joinNCT05573893 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Berlin, Wuppertal
- Age
- 18 years and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - Phase 1Not yet taking people in GermanyA First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
- Where
- Essen, Magdeburg
- Age
- 18 years and over
- People
- 30 worldwide
- Run by
- Affibody AB
See details and how to join2024-518360-13-00 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Freiburg im Breisgau, Heidelberg, Ulm
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 3Taking peopleA clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
- Where
- Cologne, Duesseldorf, Essen, Frankfurt am Main, Hamburg, Hildesheim, Moenchengladbach, Muenster, Munich, Schwerte, Ulm, Witten
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- WSG Women's Cancer Study Group GmbH
See details and how to join2024-511392-15-00 - Phase 3Not yet taking people in GermanyElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Aschaffenburg, Augsburg, Berlin, Dessau-Rosslau, Duesseldorf, Essen, Georgsmarienhuette, Heidelberg, Moenchengladbach, Worms
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseCompletedAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Where
- Essen, München
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Jules Bordet Institute
See details and how to joinNCT02102165 - Phase 3Taking peoplePhase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- Where
- Cologne, Essen, Frankfurt, Hamburg, Hildesheim, Mönchengladbach, München, Münster, Schwerte, Ulm
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Women's Cancer Study Group GmbH
See details and how to joinNCT07281833 - Phase 2Taking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Aschaffenburg, Augsburg, Dresden, Essen, Potsdam, Worms
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - Phase 1Not yet taking people in GermanyFirst-in-Women Study Evaluating the Safety of Lutetium-177 Radioligand Therapy in Metastatic Triple-Negative Breast Cancer
- Where
- Aachen, Duesseldorf
- Age
- 18 years and over
- People
- 18
- Run by
- Universitaetsklinikum Aachen AöR
See details and how to join2025-524027-49-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Erlangen
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - No phaseTaking peopleElacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
- Where
- Freiburg im Breisgau, Paderborn, Ravensburg
- Age
- 18 years and over
- People
- 500
- Run by
- iOMEDICO AG
See details and how to joinNCT07563595 - Phase 2Not yet taking people in GermanyA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Velbert
- Age
- 18 years and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - Phase 2Taking peopleDiscontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized low-intervention phase II trial of the AIO working groups breast cancer and quality of life
- Where
- Berlin, Bremen, Dresden, Georgsmarienhuette, Gerlingen, Hamburg, Leer (ostfriesland), Mainz, Muelheim an der Ruhr, Oberhausen, Ravensburg, Regensburg, Singen (hohentwiel), Soest-Paradiese, Velbert
- Age
- 18 years and over
- People
- 120
- Run by
- Institut fuer Klinische Krebsforschung IKF GmbH
See details and how to join2023-504141-31-00 - Phase 1/2Taking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00 - Phase 1/2Taking peopleStudy of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
- Where
- Essen, Jena
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521911-38-00 - Phase 2Taking peopleInvestigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
- Where
- Berlin, Bielefeld, Bonn, Eschweiler, Essen, Frankfurt Am Main, Georgsmarienhuette, Goslar, Munich, Troisdorf, Tuebingen, Witten
- Age
- 18 years to 64 years
- People
- 140 worldwide
- Run by
- Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00 - Phase 1Taking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Cologne, Essen, Munich, Rostock
- Age
- 18 years and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - Phase 2Taking peopleTrastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
- Where
- Berlin, Bottrop, Duesseldorf, Eschweiler, Essen, Frankfurt Am Main, Muenster, Munich, Oldenburg, Potsdam, Regensburg, Schwerte, Witten, Wuppertal
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- SOLTI Breast Cancer Research Group
See details and how to joinNCT07371585 · EU 2025-521805-41-00 - Phase 3Taking peopleFDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
- Where
- Essen, Muenster, Munich
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT06877949 · EU 2023-508591-11-00 - No phaseTaking peoplePraegnant Breast Cancer: Early/Advanced/Metastatic
- Where
- Aachen, Amberg, Ansbach, Augsburg, Bamberg, Bayreuth, Berlin, Böblingen, Bonn, Bottrop, Chemnitz, Darmstadt, Deggendorf, Donauwörth, Dresden, Düsseldorf, Eggenfelden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Fürstenwalde, Fürth, Georgsmarienhütte, Halle, Hamburg, Heidelberg, Herne, Hösbach, Kaiserslautern, Karlsruhe, Kassel, Kiel, Koblenz, Langen, Leer, Leipzig, Lübeck, Mannheim, Mayen, München, Neuruppin, Nürtingen, Ostfildern, Paderborn, Recklinghausen, Regensburg, Rüdersdorf, Stralsund, Torgau, Tübingen, Ulm, Wetzlar, Würselen, Würzburg
- Age
- 18 years to 99 years
- People
- 13,500
- Run by
- University Hospital Tuebingen
See details and how to joinNCT02338167 - No phaseTaking peopleCATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
- Where
- Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg, Stuttgart, Tübingen, Ulm, Würzburg
- Age
- 14 years to 100 years
- People
- 5,000
- Run by
- German Cancer Research Center
See details and how to joinNCT05652569